View in EDS HTML Full Text PDF Full Text

Inosine shapes PD-1 blockade responses and synergizes with dual PD-1/CTLA-4 immunotherapy to enhance antitumor immunity.

Saved in:
Bibliographic Details
Title: Inosine shapes PD-1 blockade responses and synergizes with dual PD-1/CTLA-4 immunotherapy to enhance antitumor immunity.
Authors: Narikawa Y; Department of Clinical Immuno Oncology, Clinical Research Institute for Clinical Pharmacology and Therapeutics, Showa Medical University, 6-11-11 Kita-Karasuyama, Setagaya-Ku, Tokyo, 157-8577, Japan.; Division of Medical Pharmacology, Department of Pharmacology, Showa Medical University School of Medicine, Tokyo, Japan.; Pharmacological Research Center, Showa Medical University, Tokyo, Japan.; Department of Otorhinolaryngology-Head and Neck Surgery, Showa Medical University School of Medicine, Tokyo, Japan., Kuramasu A; Department of Clinical Immuno Oncology, Clinical Research Institute for Clinical Pharmacology and Therapeutics, Showa Medical University, 6-11-11 Kita-Karasuyama, Setagaya-Ku, Tokyo, 157-8577, Japan., Hosonuma M; Department of Clinical Immuno Oncology, Clinical Research Institute for Clinical Pharmacology and Therapeutics, Showa Medical University, 6-11-11 Kita-Karasuyama, Setagaya-Ku, Tokyo, 157-8577, Japan.; Division of Medical Pharmacology, Department of Pharmacology, Showa Medical University School of Medicine, Tokyo, Japan.; Pharmacological Research Center, Showa Medical University, Tokyo, Japan.; Division of Medical Oncology, Department of Medicine, Showa Medical University School of Medicine, Tokyo, Japan., Murayama M; Department of Clinical Immuno Oncology, Clinical Research Institute for Clinical Pharmacology and Therapeutics, Showa Medical University, 6-11-11 Kita-Karasuyama, Setagaya-Ku, Tokyo, 157-8577, Japan.; Division of Medical Pharmacology, Department of Pharmacology, Showa Medical University School of Medicine, Tokyo, Japan.; Pharmacological Research Center, Showa Medical University, Tokyo, Japan.; Department of Otorhinolaryngology-Head and Neck Surgery, Showa Medical University School of Medicine, Tokyo, Japan., Funayama E; Department of Clinical Immuno Oncology, Clinical Research Institute for Clinical Pharmacology and Therapeutics, Showa Medical University, 6-11-11 Kita-Karasuyama, Setagaya-Ku, Tokyo, 157-8577, Japan.; Pharmacological Research Center, Showa Medical University, Tokyo, Japan.; Division of Pharmacology, Department of Pharmacology, Toxicology and Therapeutics, School of Pharmacy, Showa Medical University, Tokyo, Japan., Sasaki A; Division of Medical Pharmacology, Department of Pharmacology, Showa Medical University School of Medicine, Tokyo, Japan.; Pharmacological Research Center, Showa Medical University, Tokyo, Japan., Baba Y; Department of Clinical Immuno Oncology, Clinical Research Institute for Clinical Pharmacology and Therapeutics, Showa Medical University, 6-11-11 Kita-Karasuyama, Setagaya-Ku, Tokyo, 157-8577, Japan., Toyoda H; Department of Clinical Immuno Oncology, Clinical Research Institute for Clinical Pharmacology and Therapeutics, Showa Medical University, 6-11-11 Kita-Karasuyama, Setagaya-Ku, Tokyo, 157-8577, Japan.; Division of Medical Pharmacology, Department of Pharmacology, Showa Medical University School of Medicine, Tokyo, Japan.; Pharmacological Research Center, Showa Medical University, Tokyo, Japan.; Department of Orthopedic Surgery, School of Medicine, Showa Medical University, Tokyo, Japan., Isobe J; Department of Hospital Pharmaceutics, School of Pharmacy, Showa Medical University, Tokyo, Japan., Tajima K; Department of Clinical Immuno Oncology, Clinical Research Institute for Clinical Pharmacology and Therapeutics, Showa Medical University, 6-11-11 Kita-Karasuyama, Setagaya-Ku, Tokyo, 157-8577, Japan., Nakashima R; Department of Clinical Immuno Oncology, Clinical Research Institute for Clinical Pharmacology and Therapeutics, Showa Medical University, 6-11-11 Kita-Karasuyama, Setagaya-Ku, Tokyo, 157-8577, Japan., Sasaki A; Department of Clinical Immuno Oncology, Clinical Research Institute for Clinical Pharmacology and Therapeutics, Showa Medical University, 6-11-11 Kita-Karasuyama, Setagaya-Ku, Tokyo, 157-8577, Japan.; Division of Medical Pharmacology, Department of Pharmacology, Showa Medical University School of Medicine, Tokyo, Japan.; Pharmacological Research Center, Showa Medical University, Tokyo, Japan., Maruyama Y; Department of Clinical Immuno Oncology, Clinical Research Institute for Clinical Pharmacology and Therapeutics, Showa Medical University, 6-11-11 Kita-Karasuyama, Setagaya-Ku, Tokyo, 157-8577, Japan.; Division of Medical Pharmacology, Department of Pharmacology, Showa Medical University School of Medicine, Tokyo, Japan.; Pharmacological Research Center, Showa Medical University, Tokyo, Japan., Yamazaki Y; Pharmacological Research Center, Showa Medical University, Tokyo, Japan.; Division of Toxicology, Department of Pharmacology, Toxicology and Therapeutics, Showa Medical University School of Pharmacy, Tokyo, Japan., Shida M; Department of Clinical Immuno Oncology, Clinical Research Institute for Clinical Pharmacology and Therapeutics, Showa Medical University, 6-11-11 Kita-Karasuyama, Setagaya-Ku, Tokyo, 157-8577, Japan., Tsurui T; Department of Clinical Immuno Oncology, Clinical Research Institute for Clinical Pharmacology and Therapeutics, Showa Medical University, 6-11-11 Kita-Karasuyama, Setagaya-Ku, Tokyo, 157-8577, Japan.; Division of Medical Pharmacology, Department of Pharmacology, Showa Medical University School of Medicine, Tokyo, Japan.; Pharmacological Research Center, Showa Medical University, Tokyo, Japan.; Division of Medical Oncology, Department of Medicine, Showa Medical University School of Medicine, Tokyo, Japan., Hirasawa Y; Division of Medical Oncology, Department of Medicine, Showa Medical University School of Medicine, Tokyo, Japan., Ariizumi H; Division of Medical Oncology, Department of Medicine, Showa Medical University School of Medicine, Tokyo, Japan., Ishiguro T; Division of Medical Oncology, Department of Medicine, Showa Medical University School of Medicine, Tokyo, Japan., Suzuki R; Division of Medical Oncology, Department of Medicine, Showa Medical University School of Medicine, Tokyo, Japan., Ohkuma R; Division of Medical Oncology, Department of Medicine, Showa Medical University School of Medicine, Tokyo, Japan., Kubota Y; Division of Medical Oncology, Department of Medicine, Showa Medical University School of Medicine, Tokyo, Japan., Sambe T; Division of Clinical Pharmacology, Department of Pharmacology, Showa Medical University School of Medicine, Tokyo, Japan., Tsuji M; Pharmacological Research Center, Showa Medical University, Tokyo, Japan., Wada S; Department of Clinical Diagnostic Oncology, Clinical Research Institute for Clinical Pharmacology and Therapeutics, Showa Medical University, Tokyo, Japan., Horiike A; Division of Medical Oncology, Department of Medicine, Showa Medical University School of Medicine, Tokyo, Japan., Kobayashi S; Clinical Research Institute for Clinical Pharmacology and Therapeutics, Showa Medical University, Tokyo, Japan., Tsunoda T; Division of Medical Oncology, Department of Medicine, Showa Medical University School of Medicine, Tokyo, Japan., Kobayashi S; Department of Otorhinolaryngology, Showa Medical University Fujigaoka Hospital, Yokohama, Japan., Kobayashi H; Department of Otorhinolaryngology-Head and Neck Surgery, Showa Medical University School of Medicine, Tokyo, Japan., Oguchi T; Division of Medical Pharmacology, Department of Pharmacology, Showa Medical University School of Medicine, Tokyo, Japan.; Pharmacological Research Center, Showa Medical University, Tokyo, Japan., Shimane T; Head and Neck Oncology Center, Showa Medical University, Tokyo, Japan., Kiuchi Y; Division of Medical Pharmacology, Department of Pharmacology, Showa Medical University School of Medicine, Tokyo, Japan.; Pharmacological Research Center, Showa Medical University, Tokyo, Japan., Yoshimura K; Department of Clinical Immuno Oncology, Clinical Research Institute for Clinical Pharmacology and Therapeutics, Showa Medical University, 6-11-11 Kita-Karasuyama, Setagaya-Ku, Tokyo, 157-8577, Japan. kyoshim1@med.showa-u.ac.jp.; Division of Medical Oncology, Department of Medicine, Showa Medical University School of Medicine, Tokyo, Japan. kyoshim1@med.showa-u.ac.jp.
Source: Cancer immunology, immunotherapy : CII [Cancer Immunol Immunother] 2025 Aug 19; Vol. 74 (9), pp. 289. Date of Electronic Publication: 2025 Aug 19.
Publication Type: Journal Article
Journal Info: Publisher: Springer Verlag Country of Publication: Germany NLM ID: 8605732 Publication Model: Electronic Cited Medium: Internet ISSN: 1432-0851 (Electronic) Linking ISSN: 03407004 NLM ISO Abbreviation: Cancer Immunol Immunother Subsets: MEDLINE
Database: MEDLINE Ultimate
Full text is not displayed to guests.
Description
ISSN:1432-0851
DOI:10.1007/s00262-025-04111-2